Comparative approaches to pharmaceutical price regulation in the European Union

Croatian Medical Journal

Volumn 43, Issue 4, 2002, Pages 453-461

  Mrazek, Monique F ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Cost control; Drug costs; Drug industry; European Union; Health policy

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; EUROPEAN UNION; HEALTH CARE COST; HEALTH CARE POLICY;

COST CONTROL; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; EUROPE; EUROPEAN UNION; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; LEGISLATION, PHARMACY; PRESCRIPTION FEES; RATE SETTING AND REVIEW;

EID: 0036688443     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. The political economy of the pharmaceutical industry
2. Is price regulation necessary? A Summary of the arguments
3. Does regulation drive out competition in pharmaceutical markets?
4. Pricing and reimbursement issues in the European economic area
5. International comparisons of health care expenditures: What we know and what we do not know
6. Reimbursement and pricing of drugs in France: An increasingly complex system
7. Pharmaceutical pricing and reimbursement policies - Denmark. LSE study on healthcare in individual countries: Worldwide survey on pharmaceutical pricing and reimbursement structures
8. Price regulation in the pharmaceutical industry: Prescription or placebo?
9. Pharmaceutical pricing and reimbursement - Austria. LSE study on healthcare in individual countries: Worldwide survey on pharmaceutical pricing and reimbursement structures
10. Pharmaceutical pricing and reimbursement - Belgium. LSE study on healthcare in individual countries: Worldwide survey on pharmaceutical pricing and reimbursement structures
11. Pharmaceutical pricing and reimbursement - Italy. LSE study on healthcare in individual countries: Worldwide survey on pharmaceutical pricing and reimbursement structures
12. Pharmaceutical pricing and reimbursement policies - Finland. LSE study on healthcare in individual countries: Worldwide survey on pharmaceutical pricing and reimbursement structures
13. International price comparisons for pharmaceuticals. Measurement and policy issues
14. The 1996 pricing and reimbursement policy in the Netherlands
15. Drug pricing and reimbursement in France. Towards a new model?
16. Pharmaceutical pricing and reimbursement - Ireland. LSE study on healthcare in individual countries: Worldwide survey on pharmaceutical pricing and reimbursement structures
17. Economic evaluation of pharmaceuticals: What are reasonable standards for clinical evidence - The Australian experience
18. The influence of economic evaluation studies on decision making. A European survey
19. Evaluation of health technology: Economic issues for health policy and policy issues for economic appraisal
20. Pricing and reimbursement of drugs in Sweden
21. Cost effective provision of disease modifying therapies for people with multiple sclerosis
22. Regulating the pharmaceutical industry
23. Regulating drug prices: Where do we go from here?
24. Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK
25. Regulating the price of the UK's drugs: Second thoughts after the government's first report
26. An evaluation of the PPRS: Is there a need for reform?
27. The German experience in reference pricing
28. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement
29. Review of the literature on reference pricing
30. Price regulation of drugs: Lessons form Germany
31. Healthcare reform and expenditure on drugs: The German situation
32. Pricing and reimbursement of pharmaceuticals in Sweden
33. A comparative analysis of the pharmaceutical market in four European countries
34. Pharmaceutical pricing and reimbursement in Spain
35. How competition lowers the costs of medicines
36. Cross-national price differences for pharmaceuticals: How large, and why?